IMMX Stock Overview
A clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Immix Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.11 |
52 Week High | US$7.75 |
52 Week Low | US$1.55 |
Beta | 0.24 |
1 Month Change | -10.21% |
3 Month Change | -36.25% |
1 Year Change | 2.93% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -42.51% |
Recent News & Updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Shareholder Returns
IMMX | US Biotechs | US Market | |
---|---|---|---|
7D | -6.2% | -0.4% | -0.6% |
1Y | 2.9% | 5.4% | 22.5% |
Return vs Industry: IMMX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: IMMX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
IMMX volatility | |
---|---|
IMMX Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IMMX's share price has been volatile over the past 3 months.
Volatility Over Time: IMMX's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 16 | Ilya Rachman | www.immixbio.com |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd.
Immix Biopharma, Inc. Fundamentals Summary
IMMX fundamental statistics | |
---|---|
Market cap | US$55.73m |
Earnings (TTM) | -US$18.21m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs IMMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMMX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$18.21m |
Earnings | -US$18.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.69 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did IMMX perform over the long term?
See historical performance and comparison